Merck KGaA’s Oschmann: Pfizer Deal Likely A One Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck KGaA’s exclusive partnering deal with Pfizer to jointly develop and commercialize the German conglomerate’s key early pipeline asset will not be a model for other collaborations, as the group’s deputy CEO-elect says it wants to progress remaining early assets alone.
You may also be interested in...
Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.